Restless legs syndrome

被引:142
作者
Ekbom, K. [1 ]
Ulfberg, J. [1 ]
机构
[1] Avesta Hosp, Karolinska Univ Hosp, Sleep Disorders Ctr, Karolinska Inst,Dept Neurol, Stockholm, Sweden
关键词
dopamine agonists; iron deficiency; periodic limb movements; restless legs syndrome; sleep; PERIODIC LIMB MOVEMENTS; OF-THE-ART; DOUBLE-BLIND; SYNDROME RLS; RISK-FACTORS; SLEEP; PREVALENCE; PLACEBO; SYMPTOMS; IRON;
D O I
10.1111/j.1365-2796.2009.02159.x
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Restless legs syndrome (RLS) is a common neurological sensory-motor disorder that is characterized by intense restlessness and unpleasant creeping sensations deep inside the lower legs. Symptoms appear when the legs are at rest and are worst in the evening and at night. They force patients to keep moving their legs, and often to get out of bed and wander about. Periodic limb movements (PLMS) are also common during sleep amongst those suffering from RLS, and sleep efficiency is severely reduced. There are idiopathic as well as symptomatic forms of RLS, the latter being associated with e.g. pregnancy, iron deficiency and chronic renal failure. A family history of RLS is very common and pedigrees in these cases suggest an autosomal-dominant transmission with high penetrance. Genetic investigations have been performed in order to identify genes associated with RLS. Several loci have been found (on chromosomes 12q, 14q, 9p, 2q, 20p and 16p). Pathophysiology of RLS remains incompletely understood. However, advanced brain imaging studies and positive results of dopaminergic treatment suggest that RLS may be generated by dopamine dysfunction locally within the central nervous system. At present, there is a wide range of treatment options including levodopa, dopamine agonists, opioids, benzodiazepines, antiepileptic drugs and iron supplements.
引用
收藏
页码:419 / 431
页数:13
相关论文
共 117 条
[1]
TREATMENT OF RESTLESS LEGS SYNDROME WITH LEVODOPA PLUS BENSERAZIDE [J].
AKPINAR, S .
ARCHIVES OF NEUROLOGY, 1982, 39 (11) :739-739
[2]
Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome [J].
Allen, R ;
Becker, PM ;
Bogan, R ;
Schmidt, M ;
Kushida, CA ;
Fry, JM ;
Poceta, JS ;
Winslow, D .
SLEEP, 2004, 27 (05) :907-914
[3]
Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset [J].
Allen, Richard P. ;
Earley, Christopher J. .
SLEEP MEDICINE, 2000, 1 (01) :11-19
[4]
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology - A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health [J].
Allen, RP ;
Picchietti, D ;
Hening, WA ;
Trenkwalder, C ;
Walters, AS ;
Montplaisi, J .
SLEEP MEDICINE, 2003, 4 (02) :101-119
[5]
Restless legs syndrome prevalence and impact - REST general population study [J].
Allen, RP ;
Walters, AS ;
Montplaisir, J ;
Hening, W ;
Myers, A ;
Bell, TJ ;
Ferini-Strambi, L .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (11) :1286-1292
[6]
Augmentation of the restless legs syndrome with carbidopa/levodopa [J].
Allen, RP ;
Earley, CJ .
SLEEP, 1996, 19 (03) :205-213
[7]
MRI measurement of brain iron in patients with restless legs syndrome [J].
Allen, RP ;
Barker, PB ;
Wehrl, F ;
Song, HK ;
Earley, CJ .
NEUROLOGY, 2001, 56 (02) :263-265
[8]
ALLEN RP, 2009, SLEEP MED 0521
[9]
[Anonymous], ALCOHOLISMUS CHRONIC
[10]
Restless legs syndrome in 218 patients: associated disorders [J].
Banno, Katsuhisa ;
Delaive, Kenneth ;
Walld, Randy ;
Kryger, Meir H. .
SLEEP MEDICINE, 2000, 1 (03) :221-229